## Diabetes management

SEPTEMBER 2019

Information was omitted from **Table 1** on page 596 of the article, Makin V, Lansang MC. Diabetes management: beyond hemoglobin  $A_{1c}$  (Cleve Clin J Med 2019; 86(9):595–600, doi:10.3949/ccjm.86a.18031.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors pose a low risk of hypoglyemia, and that should have been noted in the table. The corrected table appears below and online.

Drug	Cardiovascular benefit	Weight loss	Low risk of hypoglycemia	Low cost
Metformin		Yes	Yes	Yes
Sulfonylureas				Yes
Meglitinides				
GLP-1 agonists	Yes	Yes	Yes	
DPP-4 inhibitors			Yes	Yes
SGLT2 inhibitors	Yes	Yes	Yes	
Thiazolidine- diones			Yes	
Colesevelam			Yes	
Alpha-glucosidase inhibitors			Yes	
Pramlintide		Yes		
Bromocriptine			Yes	
Insulin				Varies by formulation